Research programme: eye disorders therapies - CombinatoRx/Fovea

Drug Profile

Research programme: eye disorders therapies - CombinatoRx/Fovea

Alternative Names: FOV 2301

Latest Information Update: 29 Mar 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator CombinatoRx; Fovea Pharmaceuticals
  • Developer Fovea Pharmaceuticals
  • Class
  • Mechanism of Action Steroid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Diabetic macular oedema

Most Recent Events

  • 09 Nov 2007 Preclinical trials in Diabetic macular oedema in France (Intravitreous)
  • 20 Feb 2006 Preclinical trials in Eye disorders in France (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top